Eiko Lifesciences Ltd — Others, 30-07-2025: Others

Eiko LifeSciences reported strong FY24-25 results, with revenue up 16.3% to ₹32.49 Cr and profit after tax nearly doubling to ₹1.74 Cr, driven by an improved EBITDA margin of 9.46%. The company is strategically expanding into logistics via EikoVivify Logistics, now with around 1,000 containers, and clinical research through Eiko Scientific Solutions LLP, planning a ₹5 Cr investment. Share capital increased by ₹0.89 Cr from call money on previously issued shares. Upcoming board meetings are scheduled to consider the financial results for the quarter and half-year. The AGM will also approve an authorized capital increase to ₹20 Cr and key director appointments.